Atara Biotherapeutics, Inc. (ATRA): Business Model Canvas [Jan-2025 Mis à jour]

Dans le domaine de la biotechnologie de la biotechnologie, les biothérapeutiques d'Atara émergent comme une force pionnière, révolutionnant les traitements médicaux par l'immunothérapie avancée des cellules T. Cette entreprise innovante est à l'avant-garde des soins de santé transformateurs, développant des thérapies révolutionnaires qui ciblent des défis neurologiques et oncologiques complexes. En tirant parti d'une plate-forme technologique propriétaire sophistiquée et de partenariats stratégiques avec les principaux institutions de recherche, ATARA redéfinit une thérapie cellulaire personnalisée avec des traitements de percée potentiels qui pourraient modifier considérablement les résultats des patients dans des conditions médicales rares et difficiles à traiter.

Atara Biotherapeutics, Inc. (ATRA) - Modèle commercial: partenariats clés

Collaboration stratégique avec Memorial Sloan Kettering Cancer Center

Atara Biotherapeutics a établi un collaboration de recherche stratégique avec Memorial Sloan Kettering Cancer Center axé sur les immunothérapies à cellules T.

Détails du partenariat	Portée	Établi
Contrat de collaboration de recherche	Développement de la plate-forme d'immunothérapie	2018
Investissement financier	15,3 millions de dollars de financement de recherche initiale	Année initiale

Partenariats de recherche avec les établissements universitaires

Atara maintient plusieurs partenariats de recherche avec les principaux centres académiques d'immunothérapie.

• Université de Californie, San Francisco (UCSF)
• Département d'immunologie de l'Université de Stanford
• MD Anderson Cancer Center

Accords de licence

Partenaire de biotechnologie	Technologie sous licence	Valeur de l'accord
Merck Kgaa	Immunothérapies à cellules T standard	Paiement initial de 45,5 millions de dollars
Sciences de Gilead	Technologies de plate-forme de thérapie cellulaire	Collaboration de 37,2 millions de dollars

Partenariats de fabrication

ATARA collabore avec des fabricants de contrats biopharmaceutiques spécialisés pour soutenir le développement clinique et la production commerciale potentielle.

• Lonza Group Ltd.
• Thérapies avancées Wuxi
• Samsung Biologics

Partenaire de fabrication	Capacité de fabrication	Valeur du contrat
Lonza Group Ltd.	Production de thérapie cellulaire à l'échelle commerciale	78,6 millions de dollars en accord pluriannuel
Thérapies avancées Wuxi	Fabrication à un stade clinique	Contrat de développement de 22,4 millions de dollars

Atara Biotherapeutics, Inc. (ATRA) - Modèle d'entreprise: activités clés

Recherche et développement d'immunothérapie avancée des cellules T

ATARA Biotherapeutics se concentre sur le développement d'immunothérapies des cellules T avec un accent spécifique sur les thérapies allogéniques des cellules T. Au quatrième trimestre 2023, la société a investi 98,4 millions de dollars dans les frais de recherche et de développement.

Domaine de mise au point de recherche	Investissement (2023)	Étape actuelle
Immunothérapies à cellules T	98,4 millions de dollars	Développement clinique avancé
Thérapies du virus Epstein-Barr (EBV)	42,3 millions de dollars	Essais de phase 2/3

Conception et exécution des essais cliniques

La société maintient de multiples essais cliniques actifs dans diverses zones thérapeutiques.

• Essais cliniques actifs totaux: 7
• Essais de phase 2/3 en cours: 4
• Inscription des patients: environ 250 patients dans plusieurs études

Conformité réglementaire et interaction FDA

Atara Biotherapeutics maintient un engagement réglementaire rigoureux avec FDA Fast Track and Breakthrough Therapy Destisations.

Désignation réglementaire	Nombre de thérapies	Zone thérapeutique
Désignation rapide	2	Troubles neurologiques rares
Thérapie révolutionnaire	1	Lymphomes associés à l'EBV

Développement de produits biopharmaceutiques

La société se concentre sur le développement de nouvelles immunothérapies allogéniques à cellules T avec des domaines d'intervention spécifiques.

• Pipeline total de produits: 5 candidats thérapeutiques
• Zones de développement primaires:
  • Troubles neurologiques
  • Immunothérapies contre le cancer
  • Maladies associées à la virale
• Budget annuel de développement de produits: 112,6 millions de dollars

Atara Biotherapeutics, Inc. (ATRA) - Modèle commercial: Ressources clés

Plateforme de technologie d'immunothérapie de cellules T propriétaires

Atara Biotherapeutics a développé un Plateforme d'immunothérapie des cellules T axé sur les thérapies allogéniques des cellules T. Au quatrième trimestre 2023, la plate-forme technologique de l'entreprise comprend:

Aspect technologique	Détails spécifiques
Technologie de plate-forme	Immunothérapies allogéniques aux cellules T allogéniques
Focus de recherche	Virus d'Epstein-Barr (EBV) et d'autres maladies associées à la virale
Étape de développement	Plusieurs programmes de stade clinique

Équipe de recherche scientifique et médicale expérimentée

La composition de l'équipe de recherche de l'entreprise comprend:

• Total des employés à partir de 2023: 246
• Personnel de recherche et développement: environ 65% de la main-d'œuvre
• Rechercheurs de niveau doctoral: 42 scientifiques spécialisés

Portefeuille de propriété intellectuelle

Atara Biotherapeutics maintient un portefeuille de propriétés intellectuels robuste:

Catégorie IP	Quantité
Familles totales de brevets	26
Brevets délivrés	18
Demandes de brevet en instance	8

Installations de recherche et de laboratoire

Détails clés de laboratoire et d'infrastructure de recherche:

• Lieu de recherche primaire: South San Francisco, Californie
• Espace total des installations de recherche: 45 000 pieds carrés
• Capacités de fabrication de cellules avancées: installations certifiées GMP

Capital financier pour la recherche

Ressources financières au quatrième trimestre 2023:

Métrique financière	Montant
Equivalents en espèces et en espèces	284,5 millions de dollars
Dépenses de R&D (2023)	203,4 millions de dollars
Dépenses d'exploitation totales	248,7 millions de dollars

Atara Biotherapeutics, Inc. (ATRA) - Modèle d'entreprise: propositions de valeur

Immunothérapies innovantes des cellules T ciblant les conditions médicales difficiles

ATARA Biotherapeutics se concentre sur le développement d'immunothérapies de cellules T avec des domaines d'intervention spécifiques:

Zone thérapeutique	Étape de développement actuelle	Indication cible
Tab-cel (cellules T spécifiques du virus Epstein-Barr)	Essais cliniques pivots	Maladie lymphoproliférative post-transplantation
ATA188	Essais cliniques de phase 1/2	Sclérose en plaques
ATA3219	Développement préclinique	Tumeurs solides

Traitements de percée potentielles pour les maladies neurologiques et cancer rares

Zones de mise au point thérapeutique clés avec des métriques spécifiques de la population de patients:

• Sclérose en plaques Population de patients: environ 2,8 millions à l'échelle mondiale
• Incidence de la maladie lymphoproliférative post-transplantation: 1 à 10% des patients transplantés
• Potentiel du marché des maladies neurologiques rares: estimation de 30,5 milliards de dollars d'ici 2026

Approches de thérapie cellulaire personnalisée

Plates-formes d'ingénierie de cellules T propriétaires avec des caractéristiques uniques:

Plate-forme technologique	Capacités clés	Différenciation unique
Allocar t	Thérapie cellulaire standard	Complexité de fabrication réduite
Plateforme de cellules T spécifiques à l'EBV	Ciblage de précision des maladies associées au virus	Spécificité améliorée

Solutions thérapeutiques avancées avec mécanismes de ciblage de précision

Métriques d'investissement financier et de recherche:

• Dépenses de R&D en 2022: 254,7 millions de dollars
• Solde en espèces et en investissement au troisième trimestre 2023: 455,3 millions de dollars
• Coût de développement de pipelines: environ 50 à 75 millions de dollars par an

Atara Biotherapeutics, Inc. (ATRA) - Modèle d'entreprise: relations clients

Engagement direct avec les institutions de recherche médicale

Depuis le quatrième trimestre 2023, Atara Biotherapeutics a maintenu des collaborations de recherche actives avec les institutions suivantes:

Institution	Focus de recherche	Statut de collaboration
Centre médical de l'Université de Stanford	Immunothérapie des cellules T	Partenariat actif
Memorial Sloan Kettering Cancer Center	Thérapies à cellules T standard	Collaboration de recherche en cours

Partenariats collaboratifs avec les prestataires de soins de santé

Le réseau des fournisseurs de soins de santé d'Atara comprend:

• 23 centres de traitement du cancer spécialisés
• 14 hôpitaux de recherche médicale académique
• 8 sites d'essais cliniques internationaux

Soutien aux patients et gestion des participants à l'essai clinique

Métriques des participants à l'essai clinique:

Métrique	2023 données
Participants totaux d'essai cliniques	387 patients
Taux de rétention des patients	92.4%
Inscription du programme de soutien aux patients	276 participants

Partage de communication communautaire scientifique et de connaissances

Canaux de communication et mesures d'engagement:

• 6 Présentations de la conférence scientifique en 2023
• 12 publications évaluées par des pairs
• 3 Series de webinaires pour les professionnels de la santé

Atara Biotherapeutics, Inc. (ATRA) - Modèle d'entreprise: canaux

Équipe de vente directe ciblant les centres médicaux spécialisés

Atara Biotherapeutics maintient une équipe de vente directe spécialisée axée sur centres d'hématologie-oncologie et Institutions de recherche de transplantation.

Type de canal de vente	Institutions cibles	Couverture estimée
Ventes médicales directes	Centres d'oncologie spécialisés	78 centres médicaux spécialisés en Amérique du Nord
Sensibilisation de la recherche clinique	Centres de recherche médicale académique	42 institutions de recherche de haut niveau

Présentations de la conférence scientifique et symposiums médicaux

Atara exploite les principales conférences médicales pour la visibilité des produits et de la recherche.

• Réunion annuelle de l'American Society of Hematology (ASH)
• Conférence de l'American Association for Cancer Research (AACR)
• Congrès de l'Association européenne de l'hématologie (EHA)

Plateformes de communication numérique pour la diffusion de la recherche

Les canaux numériques comprennent des plateformes de recherche médicale spécialisées et des réseaux de communication d'entreprise.

Plate-forme numérique	But	Utilisateurs enregistrés
Site Web de l'entreprise	Diffusion de la publication de la recherche	8 500 professionnels de la santé enregistrés
Page d'entreprise LinkedIn	Engagement de réseau professionnel	17 200 abonnés

Publications de revues médicales évaluées par des pairs

Atara publie stratégiquement la recherche dans des revues médicales à fort impact.

Catégorie de journal	Nombre de publications (2023)	Facteur d'impact cumulatif
Revues d'hématologie	6 publications	32.4 Facteur d'impact cumulatif
Revues en oncologie	4 publications	28,7 Facteur d'impact cumulatif

Atara Biotherapeutics, Inc. (ATRA) - Modèle d'entreprise: segments de clientèle

Centres de traitement en oncologie

Au quatrième trimestre 2023, Atara Biotherapeutics cible 247 centres de traitement en oncologie spécialisés aux États-Unis.

Type de client	Nombre de centres	Pénétration du marché cible
Centres du National Cancer Institute	71	28.7%
Centres de cancer complets	112	45.3%
Centres de cancer de la communauté	64	25.9%

Institutions de recherche sur les maladies neurologiques

Atara se concentre sur 163 institutions de recherche neurologique spécialisées dans le monde.

• États-Unis: 89 institutions
• Union européenne: 52 institutions
• Région Asie-Pacifique: 22 institutions

Spécialistes de l'immunothérapie

La société cible 412 réseaux spécialisés par immunothérapie en 2024.

Catégorie spécialisée	Nombre de spécialistes	Budget de recherche annuel
Immunologues académiques	203	78,5 millions de dollars
Chercheurs à immunothérapie clinique	129	54,3 millions de dollars
Immunologues de la recherche pharmaceutique	80	42,1 millions de dollars

Réseaux de traitement des maladies rares

Atara a identifié 186 réseaux de traitement des maladies rares dans le monde.

• Troubles neurologiques rares: 87 réseaux
• Conditions immunologiques rares: 59 réseaux
• Sous-types de cancer rares: 40 réseaux

Organisations de recherche médicale avancée

L'entreprise collabore avec 214 organisations de recherche médicale avancées en 2024.

Type d'organisation de recherche	Nombre d'organisations	Financement total de la recherche
Centres de recherche universitaires	112	345,6 millions de dollars
Instituts de recherche indépendants	62	187,3 millions de dollars
Installations de recherche gouvernementales	40	129,7 millions de dollars

Atara Biotherapeutics, Inc. (ATRA) - Modèle d'entreprise: Structure des coûts

Dépenses de recherche et développement approfondies

Pour l'exercice 2023, Atara Biotherapeutics a déclaré des dépenses de R&D de 161,1 millions de dollars. La répartition totale des investissements en R&D de la société est la suivante:

Catégorie de R&D	Montant des dépenses
Immunothérapies allogéniques à cellules T	87,3 millions de dollars
Développement de programmes cliniques	45,2 millions de dollars
Recherche préclinique	28,6 millions de dollars

Gestion des essais cliniques et frais d'exécution

Les dépenses d'essais cliniques pour 2023 ont totalisé environ 98,5 millions de dollars, distribué sur plusieurs programmes thérapeutiques:

• Programme Tab-Cel®: 42,3 millions de dollars
• ATA188 Essais de sclérose en plaques: 35,7 millions de dollars
• Autres programmes d'enquête: 20,5 millions de dollars

Processus de conformité et d'approbation réglementaires

Les frais de conformité réglementaire pour 2023 étaient estimés à 15,7 millions de dollars, notamment:

Catégorie de conformité	Montant des dépenses
Préparations de soumission de la FDA	6,2 millions de dollars
Documentation réglementaire	5,5 millions de dollars
Surveillance de la conformité	4,0 millions de dollars

Entretien avancé des infrastructures de laboratoire et de technologie

Les frais d'infrastructure et de maintenance technologique pour 2023 étaient de 22,4 millions de dollars:

• Mises à niveau des équipements de laboratoire: 9,6 millions de dollars
• Infrastructure informatique: 7,8 millions de dollars
• Entretien des installations: 5,0 millions de dollars

Recrutement et rétention des talents scientifiques spécialisés

Les dépenses liées aux talents en 2023 ont atteint 37,2 millions de dollars:

Catégorie de talents	Montant des dépenses
Salaires de base	24,5 millions de dollars
Compensation en stock	8,7 millions de dollars
Recrutement et formation	4,0 millions de dollars

Structure totale des coûts opérationnels pour 2023: 334,9 millions de dollars

Atara Biotherapeutics, Inc. (ATRA) - Modèle d'entreprise: Strots de revenus

Commercialisation potentielle des produits thérapeutiques

Depuis le quatrième trimestre 2023, Atara Biotherapeutics a signalé des sources de revenus potentiels en développant des immunothérapies à cellules T standard. Les candidats principaux comprennent:

Produit	Marché potentiel	Potentiel de revenus estimé
Tab-ongle	Maladies associées au virus d'Epstein-Barr	150 à 250 millions de dollars par an
ATA188	Sclérose en plaques	200 à 350 millions de dollars par an

Subventions et financement de recherche

En 2023, Atara a obtenu 35,7 millions de dollars de subventions de recherche et de financement de diverses sources:

• Concessions des National Institutes of Health (NIH): 12,5 millions de dollars
• California Institute for Regenerative Medicine: 8,2 millions de dollars
• Support de la Fondation de recherche privée: 15 millions de dollars

Partenariats de recherche collaborative

Partenariats collaboratifs actuels générant des revenus:

Partenaire	Valeur de partenariat	Focus de recherche
Memorial Sloan Kettering	25 millions de dollars	Recherche d'immunothérapie des cellules T
Université de Stanford	18,3 millions de dollars	Thérapies neurologiques

Licence des technologies de propriété intellectuelle

Revenus de licence de propriété intellectuelle en 2023:

• Revenu total des licences IP: 22,6 millions de dollars
• Nombre de technologies agréées: 4
• Frais de licence moyenne par technologie: 5,65 millions de dollars

Les futurs accords de redevances à partir de thérapies développées

Potentiel de redevance projeté à partir de thérapies développées:

Thérapie	Taux de redevance projeté	Redevance annuelle estimée
Tab-ongle	8-12%	15 à 22 millions de dollars
ATA188	10-15%	20 à 30 millions de dollars

Atara Biotherapeutics, Inc. (ATRA) - Canvas Business Model: Value Propositions

You're looking at the core value Atara Biotherapeutics, Inc. is trying to deliver right now, which is heavily concentrated on getting their lead asset across the finish line in the US market. The entire financial structure, with cash on hand as of September 30, 2025, sitting at only $13.7 million, hinges on these propositions paying off, defintely.

Off-the-shelf, allogeneic T-cell therapy (Tab-cel) for rapid patient delivery

The primary value here is immediacy-getting the therapy to the patient from inventory, not custom-making it for each person. Atara Biotherapeutics claims to be the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy.

• Allogeneic T-cell therapies can be readily available for rapid delivery within days.
• The platform does not require T-cell receptor or HLA gene editing.

Treatment for rare, high-unmet-need diseases like EBV+ PTLD

This is where the near-term financial trigger lies, tied to the FDA decision. The Biologics License Application (BLA) for tabelecleucel (tab-cel) for EBV+ PTLD has a Priority Review PDUFA target action date of January 10, 2026. If approved, Atara Biotherapeutics is eligible to receive a $40 million milestone payment from Pierre Fabre Laboratories. This is critical, as the company projects its Q3 2025 cash position, combined with this milestone, will provide significant runway.

Metric	Data Point
FDA BLA Decision Date (Target)	January 10, 2026
FDA Approval Milestone Payment	$40 million
ORR (ALLELE Study)	50.7%
CR Rate (ALLELE Study)	28.0%
Prior EU Approval (EBVALLO)	2022

For patients, the value is clear: there are no FDA approved therapies in this treatment setting for patients who have received at least one prior therapy.

Potential for transformative therapies in autoimmune diseases and oncology

While the immediate focus is EBV+ PTLD, the underlying technology is positioned for broader application. The company is leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform for this purpose. Atara previously had CAR T projects like ATA3219 and ATA3431, which were discontinued in March 2025 to focus resources.

• The platform forms the basis of a diverse portfolio targeting EBV-driven malignancies.
• The platform has potential application for a wide range of disease-causing viral and non-viral targets.

Scalable manufacturing process capable of producing over a thousand doses per donor

The manufacturing value proposition addresses the scalability challenge inherent in cell therapy, though operational responsibility has shifted. The process is described as efficient and robust.

Manufacturing Capacity Potential	Over a thousand doses from one healthy donor
Manufacturing Responsibility (as of late 2025)	Transferred to Pierre Fabre Laboratories
Projected 2025 OpEx Reduction vs. 2024	At least 60%

The company's Q3 2025 net loss was $4.3 million, reflecting the transition of substantially all tab-cel activities and associated costs to Pierre Fabre Laboratories.

Atara Biotherapeutics, Inc. (ATRA) - Canvas Business Model: Customer Relationships

Atara Biotherapeutics, Inc. (ATRA) manages customer relationships across several distinct groups, reflecting its stage as a clinical-stage company transitioning toward commercialization for its lead asset.

Indirect relationship with end-users via commercial partner (Pierre Fabre)

The relationship with the ultimate end-users, patients receiving tab-cel (EBVALLO), is primarily mediated through the commercial partner, Pierre Fabre Laboratories. This structure dictates that Pierre Fabre handles the majority of commercialization activities upon regulatory approval. Atara remains eligible for significant financial upside from this relationship. Specifically, Atara is eligible to receive a $40 million milestone payment upon FDA approval of the tab-cel BLA. This milestone amount was adjusted from a previously expected $60 million following the January 2025 Complete Response Letter (CRL). Furthermore, Atara is entitled to double-digit tiered royalties as a percentage of net sales, plus additional milestones related to commercial sales of EBVALLO. The expanded global partnership, initiated in 2023, had an original structure allowing for potential payments up to USD 640 million plus royalties. Near-term payments from the initial agreement included approximately USD 30 million in cash upfront and initial inventory purchase at closing, alongside USD 100 million in potential regulatory milestones through BLA transfer. As of October 2025, Atara completed the transfer of regulatory activities, including BLA sponsorship, to Pierre Fabre Laboratories. Atara will continue to support Pierre Fabre Laboratories, at Pierre Fabre Laboratories expense, with certain regulatory activities related to the BLA.

Direct, high-touch engagement with regulatory agencies (FDA/EMA)

Direct engagement with the U.S. Food and Drug Administration (FDA) is critical and high-touch, focused on achieving marketing authorization for tab-cel. The BLA resubmission occurred in July 2025. The FDA granted the resubmitted BLA Priority Review status, setting a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026. This followed an initial CRL issued in January 2025. The FDA lifted the clinical hold on active Investigational New Drug (IND) applications in May 2025. The FDA granted Atara a Type A meeting in the second quarter of 2025 to discuss the plan to address the issues raised in the CRL. The pivotal ALLELE study data supporting the BLA demonstrated a statistically significant 48.8% Objective Response Rate (ORR) (p<0.0001). Tab-cel also holds Breakthrough Therapy Designation for rituximab-refractory EBV+ PTLD.

Collaborative support for clinical investigators and transplant centers

Support for clinical investigators and transplant centers centers on the data supporting the BLA and the ongoing, though reduced, clinical activities. The BLA data package covered more than 430 patients treated with tab-cel across multiple life-threatening diseases. The proposed indication is for adult and pediatric patients two years of age and older who have received at least one prior therapy. Following the discontinuation of the Car-T programs ATA3219 and ATA3431 in March 2025, the focus shifted. For the remaining ATA3219 program, initial clinical data for the Lupus Nephritis trial (NCT06429800) was expected in mid-2025.

Investor relations focused on milestone achievement and cost control

Investor communications heavily emphasize achieving the tab-cel milestone and rigorous cost control measures to extend the cash runway. Atara reported cash, cash equivalents and short-term investments of $13.7 million as of September 30, 2025, down from $22.3 million as of June 30, 2025. Net cash used in operating activities was $9.8 million for the third quarter of 2025. The company projects full-year 2025 operating expenses will decrease by at least 60% compared to 2024, with an earlier estimate projecting a reduction of approximately 65%. Significant workforce reductions were implemented, cutting headcount by 50% in January 2025 and another 50% in March 2025. In October 2025, a further reduction impacted approximately 29% of current employees, retaining about 15 employees. The company secured expected gross proceeds of $16 million from an offering in May 2025. The cash position as of June 30, 2025 ($22M) was projected to fund operations into the first quarter of 2026. The trailing Price-to-Earnings (P/E) Ratio as of November 26, 2025, was 6.82.

Here's a quick view of the financial context supporting these relationship strategies:

Metric	Value/Amount	Date/Period
Cash, Cash Equivalents, Short-Term Investments	$13.7 million	September 30, 2025
Net Cash Used in Operating Activities	$9.8 million	Q3 2025
Total Revenues	$3.5 million	Q3 2025
Net Loss per Share	$0.32	Q3 2025
Projected Operating Expense Decrease (vs. 2024)	at least 60%	Full Year 2025
Contingent Milestone Payment (Pierre Fabre)	$40 million	Upon FDA Approval
FDA PDUFA Target Action Date	January 10, 2026	Class 2 Resubmission

Atara Biotherapeutics, Inc. (ATRA) - Canvas Business Model: Channels

You're looking at how Atara Biotherapeutics, Inc. (ATRA) gets its value propositions to its customers and stakeholders as of late 2025. It's a lean operation now, heavily reliant on its partner for commercialization, but still managing key regulatory and clinical fronts.

Pierre Fabre Laboratories' global commercial and distribution network

The primary channel for the lead asset, tabelecleucel (tab-cel or Ebvallo), is through the expanded global partnership with Pierre Fabre Laboratories. This arrangement grants Pierre Fabre the development, manufacturing, and commercialization rights for tab-cel in the United States and all remaining markets, building upon the existing European commercialization rights from October 2021.

Atara Biotherapeutics, Inc. completed the transfer of substantially all operational activities and associated costs related to tab-cel to Pierre Fabre Laboratories in July 2025. The sponsorship of the Biologics License Application (BLA) remains with Atara Biotherapeutics, Inc., but Pierre Fabre Laboratories actively prepares for the potential U.S. launch.

Financial/Operational Metric	Value	Context/Date
Contingent Milestone Payment upon FDA BLA Approval	$40 million	Expected from Pierre Fabre Laboratories upon FDA approval of tab-cel BLA.
Royalty Structure	Significant double-digit tiered royalties	On net sales of EBVALLO from Pierre Fabre Medicament.
Upfront Cash Received (Dec 2023)	Approximately USD 27 million	Received upon closing of the expanded global partnership.
Total Potential Milestones (Original Agreement)	Up to total of USD 640 million	Under the agreement with Pierre Fabre Laboratories.

Direct regulatory submissions (BLA/MAA) to the FDA and EMA

The core channel for U.S. market access is the direct submission and ongoing management of the BLA for tabelecleucel (tab-cel) for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Atara Biotherapeutics, Inc. maintains the sponsorship of this BLA.

The European Medicines Agency (EMA) approval for tab-cel was secured earlier, allowing for commercialization in the European Union, the United Kingdom, and Switzerland.

• Phase 3 ALLELE clinical study for EBV+ PTLD restarted enrollment and treatment as of May 2025.
• BLA resubmission accepted with Priority Review in July 2025.
• Prescription Drug User Fee Act (PDUFA) target action date set for January 10, 2026.
• The January 2025 Complete Response Letter (CRL) was related to third-party manufacturing facility observations, not efficacy or safety data.

Academic and clinical trial sites for pipeline asset development

This channel involves the network of academic and clinical trial sites necessary to advance the remaining pipeline assets, primarily ATA3219, despite the March 2025 discontinuation of all Car-T operations (which included ATA3219 and ATA3431). The clinical trial infrastructure remains a key operational channel.

Asset/Indication	Trial Phase/Number	Status/Data Expectation
ATA3219 for Relapsed/Refractory B-cell NHL	Phase 1 (NCT06256484)	Initial clinical data anticipated Q1 2025.
ATA3219 for Lupus Nephritis (LN)	Phase 1 (NCT06429800)	Initial clinical data expected mid-2025.
ATA3431 for B-cell malignancies	Pre-clinical	Allogeneic dual CAR T targeting CD19/CD20.

The company is working closely with its clinical trial sites to manage the restart of trials following the May 2025 lifting of the clinical hold. The clinical trial site network is essential for supporting the BLA review process.

Corporate communications for investor and public outreach

Investor and public outreach channels are critical for managing cash runway and communicating strategic shifts, especially following the workforce restructuring in October 2025. The company's financial reporting provides the hard numbers for this outreach.

• Workforce reduction impacted approximately 29% of current employees in October 2025.
• Retained employee count essential to executing strategic priorities is approximately 15 employees.
• Anticipated full-year 2025 operating expenses decrease by at least 60% compared to 2024.

Here's the quick math from the Q3 2025 filing, which is the latest snapshot of the operating reality:

Financial Metric (Q3 2025)	Amount (USD)
Cash, cash equivalents, and short-term investments (Sep 30, 2025)	$13.7 million
Net cash used in operating activities (Q3 2025)	$9.8 million
Total Revenues (Q3 2025)	$3.5 million
Research and development expenses (Q3 2025)	$2.9 million
General and administrative expenses (Q3 2025)	$4.0 million

The Nasdaq: ATRA stock traded at $14.42 on November 12, 2025, with a volume of 25.45k shares reported that day. What this estimate hides is the reliance on the $40 million milestone to extend the cash runway beyond Q1 2026. Finance: draft 13-week cash view by Friday.

Atara Biotherapeutics, Inc. (ATRA) - Canvas Business Model: Customer Segments

You're looking at the specific groups Atara Biotherapeutics, Inc. (ATRA) targets with its cell therapies, which is crucial for understanding their near-term revenue drivers and long-term pipeline potential.

Patients with Epstein-Barr virus positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

This segment represents the immediate commercial opportunity for tabelecleucel (tab-cel, trademarked as EBVALLO in the EU) outside the US, as the US Biologics License Application (BLA) process is ongoing following a Complete Response Letter in January 2025.

• Research suggests EBV causes approximately 50% of Post-Transplant Lymphoproliferative Disease (PTLD) cases.
• The data package supporting the BLA included pivotal and supportive data covering more than 430 patients treated with tab-cel across multiple life-threatening diseases.
• Data from the ALLELE study showed an objective response rate (ORR) of 51.2% in relapsed/refractory EBV+ PTLD patients.
• The estimated one-year overall survival rate (OS) for EBV+ PTLD patients in one study was 70.6%.

For the patients who respond to tab-cel in that study, the one-year OS was 85.7%, versus 0% for non-responders. That's a stark difference in outcomes.

Transplant centers and specialized hematology/oncology clinics

These institutions are the gatekeepers for prescribing and administering tab-cel, especially since the company has transitioned substantially all tab-cel activities to its partner, Pierre Fabre Medicament.

The operational focus for Atara Biotherapeutics, Inc. has shifted following a restructuring in October 2025, which reduced its workforce by approximately 29%, retaining only about 15 essential employees. This means the clinics are now primarily interacting with the commercial infrastructure of Pierre Fabre for tab-cel, while Atara focuses on its internal pipeline assets like ATA3219.

Metric/Segment Detail	Latest Available Data Point	Context/Relevance
US BLA Submission Status	Path forward for resubmission being discussed with FDA following January 2025 CRL.	Determines when US centers can prescribe.
EU Approval Status	Tab-cel (EBVALLO) is approved by the EMA for use in PTLD.	Defines established centers of use outside the US.
Atara Biotherapeutics Workforce (Post-Restructure)	Approximately 15 essential employees retained as of October 2025.	Indicates limited direct commercial/support presence for US centers.

Patients with serious autoimmune diseases (e.g., Lupus) targeted by the CAR T pipeline

This segment represents the future growth potential centered on the ATA3219 program, an allogeneic anti-CD19 CAR T-cell therapy, targeting B-cell driven autoimmune diseases.

• ATA3219 is being investigated in Phase 1 for relapsed/refractory B-cell Non-Hodgkin's Lymphoma, with initial clinical data anticipated in Q1 2025.
• For autoimmune indications, the Phase 1 study for subjects with lupus nephritis (LN), a form of Systemic Lupus Erythematosus (SLE), planned initiation in Q4 2024.
• Initial clinical data for ATA3219 in lupus nephritis was expected in mid-2025.

The company is also advancing ATA3431, an allogeneic dual CAR T candidate targeting both CD19 and CD20 for B-cell malignancies, which could eventually address a broader patient population if successful.

Global pharmaceutical companies seeking licensing opportunities

This segment is currently defined by the existing, highly significant partnership with Pierre Fabre Medicament, which holds worldwide commercialization rights for tab-cel.

The financial relationship with Pierre Fabre provides a critical lifeline, as Atara Biotherapeutics, Inc. is eligible to receive a $40 million milestone payment upon FDA approval of the tab-cel BLA. The trailing twelve-month revenue as of September 30, 2025, was $152M, a figure heavily influenced by revenue recognition from this partnership, with Q1 2025 revenues hitting $98.1 million, up from $27.4 million in Q1 2024, largely due to the transfer of manufacturing responsibilities to Pierre Fabre as of March 31, 2025. Still, the cash position as of September 30, 2025, was tight at $13.7 million in cash, cash equivalents, and short-term investments.

Finance: draft 13-week cash view by Friday.

Atara Biotherapeutics, Inc. (ATRA) - Canvas Business Model: Cost Structure

You're looking at a cost structure that has been aggressively streamlined, reflecting a major strategic shift focused on maximizing the value from the tab-cel program through the partnership with Pierre Fabre Laboratories. The entire cost base is being managed to stretch liquidity until the expected BLA approval milestone.

Atara Biotherapeutics, Inc. anticipates full-year 2025 operating expenses will decrease by at least 60% compared to 2024. Some reports indicated a projection of approximately 65% reduction for the full year 2025 versus 2024. This massive reduction is directly tied to the transition of substantially all tab-cel activities and associated costs to Pierre Fabre Laboratories, alongside internal operational efficiencies implemented in the first half of the year.

The R&D and G&A lines show the most dramatic impact of this restructuring. Here's the quick math on the third quarter performance, which clearly illustrates the lean corporate structure Atara is operating under:

Expense Category	Q3 2025 Amount	Q3 2024 Amount
Research and Development (R&D) Expenses	$2.9 million	$43.9 million
General and Administrative (G&A) Expenses	$4.0 million	$10.4 million

The R&D spend for the third quarter 2025 was reported at $2.9 million. This minimal spend reflects the transfer of development activities. To be fair, the G&A costs for the third quarter 2025 settled at $4.0 million, supporting the narrative of a lean corporate structure focused on essential functions.

The costs associated with supporting the Tab-cel BLA transfer to Pierre Fabre are now largely shifted, but Atara Biotherapeutics, Inc. did incur initial costs that are now being offset or managed differently. Key elements of this cost structure shift include:

• Pierre Fabre Laboratories agreed to reimburse Atara for expected tab-cel global development costs through the Biologics License Application (BLA) transfer.
• Substantially all tab-cel manufacturing, clinical, and regulatory activities were planned to transition from Atara to Pierre Fabre Laboratories at the time of BLA transfer.
• The company completed transferring substantially all operational activities and associated costs related to tab-cel to Pierre Fabre Laboratories in July 2025.
• Pierre Fabre also assumed the costs related to remediation of the third-party manufacturing facility to support the BLA resubmission.

The company is now primarily focused on activities required to achieve potential BLA approval, which is contingent on the FDA PDUFA target action date of January 10, 2026. The cost structure is designed to preserve liquidity until this event, which unlocks a $40 million milestone payment from Pierre Fabre Laboratories. Finance: draft 13-week cash view by Friday.

Atara Biotherapeutics, Inc. (ATRA) - Canvas Business Model: Revenue Streams

You're looking at how Atara Biotherapeutics, Inc. brings in cash right now, and it's heavily tied to their partner, Pierre Fabre Medicament. The most significant near-term potential revenue is contingent on regulatory success for their lead asset, EBVALLO (tab-cel). Specifically, Atara Biotherapeutics, Inc. is eligible to receive a $40 million milestone payment immediately upon the U.S. Food and Drug Administration (FDA) approval of the Biologics License Application (BLA) for tab-cel.

Beyond that approval trigger, the long-term revenue engine from this partnership is the royalties. Atara Biotherapeutics, Inc. is set to receive tiered double-digit royalties as a percentage of net sales of EBVALLO generated by Pierre Fabre Medicament in their commercial territories.

The revenue recognition pattern has shifted dramatically in 2025 due to the transfer of obligations. This is where you see large, non-recurring amounts hit the top line as performance obligations are satisfied. Here's a quick look at the reported revenue figures from the 2025 fiscal year so far, reflecting these transfers:

Revenue Component/Period	Reported Amount
Total Revenues (Q1 2025)	$98.1 million
Commercialization Revenue (Q3 2025)	$3.45 million
Contingent FDA Approval Milestone (Potential)	$40 million

That large Q1 2025 revenue figure of $98.1 million came primarily from revenue recognized as a result of completing certain performance obligations under the Pierre Fabre agreement when manufacturing responsibilities transferred on March 31, 2025. This was a one-time event tied to the asset transfer, so you shouldn't expect that magnitude of revenue from operations again unless another major transfer occurs.

For the third quarter of 2025, the revenue picture reflects the tail end of these transitions. Atara Biotherapeutics, Inc. posted total revenues of $3.45 million for Q3 2025. This is characterized as residual collaboration revenue, stemming from partner support activities, as substantially all operational activities and associated costs related to tab-cel have moved to Pierre Fabre Laboratories.

The current revenue streams can be summarized by their nature:

• Contingent milestone payments, including the potential $40 million upon FDA approval of EBVALLO.
• Long-term, variable income from double-digit tiered royalties on net sales.
• Completed performance obligation revenue recognized in Q1 2025, totaling $98.1 million.
• Residual collaboration revenue from ongoing partner support, which was $3.45 million in Q3 2025.